Preparation method and use method of sPL temperature-sensitive gel for treating type 2 diabetes mellitus
By preparing sPL temperature-sensitive gel, combining the factors of platelets and bone marrow mesenchymal stem cell inducer fluid, the problem of insufficient number and types of factors in platelet lysate was solved, and long-term pancreatic function regulation and insulin resistance were achieved, which significantly improved 2 The treatment effect of type diabetes.
Patent Information
- Application Number
- CN202411077468.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-15
AI Technical Summary
When treating type 2 diabetes, the existing platelet lysates have low number of inflammation control and immunomodulatory factors, few types, and do not last long.
Prepare a sPL temperature-sensitive gel, and activate platelets by adding puerarin to the blood, combining factors in bone marrow mesenchymal stem cell inducing fluid, prepare platelets and extracellular vesicle lysate, and mix them with chitosan-poloxam The gel combines to form a sustained-release therapeutic agent and is injected to the periphery of the dorsal pancreatic artery.
It significantly improves the types and quantities of anti-inflammatory and antioxidant factors, extends the drug residence time, improves the therapeutic effect, lasts to regulate the function of the pancreas and surrounding tissues, and improves the insulin resistance state.
Smart Images

Figure CN118948752A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of drugs for treating type 2 diabetes, and in particular to a preparation method and a use method of a SPL temperature-sensitive gel for treating type 2 diabetes. Background Art
[0002] Diabetes is a chronic disease caused by multiple factors that affects the health of a large part of the world's population. In the past 40 years, the number of adults with diabetes worldwide has increased significantly, and 90-95% of them are type 2 diabetes mellitus (T2DM). T2DM is a metabolic chronic disease characterized by insulin resistance and elevated blood glucose levels. Unlike type 1 diabetes, type 2 diabetes is relatively heterogeneous and very complex, involving many pathophysiological mechanisms that affect the function of the pancreas and other metabolic organs (β cells, adipose tissue, liver and muscle, etc.), and the treatment of this disease is very challenging. At present, there are a large number of drugs and drug combinations that can control blood glucose levels, such as adiponectin, GLP-1 peptide receptor agonists, etc., but these drugs cannot reverse the disease and control the occurrence of complications.
[0003] In the existing methods of treating diabetes using platelet lysate, the number and types of inflammation control and immune regulation factors in the platelet lysate are low, and the effects are not long-lasting. Summary of the invention
[0004] The present invention aims to solve the problems of low number, few types and short-lasting effects of inflammation control and immune regulation factors in existing platelet lysate, and to provide a preparation method and use method of SPL thermosensitive gel for treating type 2 diabetes.
[0005] The method for preparing the sPL thermosensitive gel for treating type 2 diabetes of the present invention comprises the following steps:
[0006] 1. Add puerarin to the blood and store it at 4°C for 24 to 36 hours; then centrifuge the blood to collect platelet-rich plasma (PRP); lyse the platelet-rich plasma to prepare platelet lysate aPL;
[0007] 2. After the bone marrow mesenchymal stem cells are cultured to complete fusion, the culture medium is replaced with induction solution and the induction culture is continued for 96 to 98 hours;
[0008] The induction solution is a DMEM / F12 basal culture medium containing 5 μg / mL to 5 mg / mL insulin, 0.5 to 5 μM dexamethasone and 0.1 to 1 ng / mL Inonotus obliquus flavonoids;
[0009] 3. Extracting extracellular vesicles from the induced bone marrow mesenchymal stem cells and resuspending them in PBS to obtain a vesicle suspension;
[0010] 4. ultrasonically lyse the vesicle suspension obtained in step 3 to obtain a vesicle lysate, and then mix the platelet lysate obtained in step 1 with the vesicle lysate to obtain an sPL mixed solution;
[0011] 5. Prepare chitosan-poloxamer gel. Mix the sPL mixed solution with the chitosan-poloxamer gel to prepare the sPL thermosensitive gel.
[0012] Furthermore, in step 1, the concentration of puerarin in the blood is 0.05-0.2 μM.
[0013] Furthermore, the preparation method of platelet lysate aPL in step 1 is:
[0014] Add CaCl to platelet-rich plasma 2 and type III collagen, frozen at -80℃ for 8-9h, thawed at 37℃ for 5-10min, and then frozen and thawed 10 times. The process of repeated freezing and thawing is: freezing at -80℃ for 1h and then thawing at 37℃ for 5-10min. The lysate after the last thawing is centrifuged and the supernatant is taken to obtain fully activated platelet lysate aPL. 2 The concentration of type III collagen in PRP is 25mmol / L, and the concentration of type III collagen in PRP is 20μg / mL.
[0015] Further, the preparation method of Inonotus obliquus flavonoids in step 2 is:
[0016] After grinding Inonotus obliquus (purchased from Special Medical Food Research and Development Center Co., Ltd.) into powder, 70% ethanol was used for heating reflux extraction at 75°C for 1 hour, and the supernatant was collected; after repeating the heating reflux extraction 3 times, the supernatants were combined and then heated and concentrated at 70°C to obtain Inonotus obliquus flavonoids.
[0017] Furthermore, the method for extracting extracellular vesicles in step 3 is:
[0018] The induced bone marrow mesenchymal stem cells were washed, cultured with DMEM / F12 basal medium for 12 to 14 hours, the culture fluid was collected, the culture fluid was centrifuged, the supernatant was taken, and centrifuged at 10,000×g at 4°C to remove cell debris; the supernatant was then transferred to an ultracentrifuge tube, ultracentrifuged at 100,000×g at 4°C for 75 to 80 minutes, and the precipitate at the bottom of the tube was retained, which was the extracellular vesicles.
[0019] Furthermore, in step 4, the platelet lysate and the vesicle suspension are mixed in a volume ratio of 1:(1-2).
[0020] Furthermore, in step five, the volume ratio of the sPL mixed solution to the chitosan-poloxamer gel is 1:(5-9).
[0021] The method for using the sPL thermosensitive gel of the present invention is as follows: injecting the sPL thermosensitive gel into the periphery of the pancreatic dorsal artery of mice.
[0022] Furthermore, the injection dosage is 0.2 mL / mouse.
[0023] The sPL thermosensitive gel prepared by the method can solidify and adhere to the periphery of the dorsal pancreatic artery, and release the factors therein slowly and persistently into the dorsal pancreatic artery, thereby regulating the function of the pancreas and surrounding tissues, improving the insulin resistance state, and enhancing the therapeutic effect of type 2 diabetes.
[0024] Beneficial effects of the present invention:
[0025] 1. The present invention utilizes CaCl 2 The platelet α granules in PRP are activated with type III collagen to release the factors therein, and the platelets are fully lysed by repeated freezing and thawing to obtain fully activated platelet lysate. In addition, before the preparation of PRP, puerarin is added to the blood for stimulation for 24 hours, which can prompt white blood cells to secrete more anti-inflammatory factors and antioxidant factors. The types and quantities of anti-inflammatory and antioxidant factors in the aPL finally prepared are rich.
[0026] 2. The present invention adds 5 μg / mL to 5 mg / mL insulin and 1 to 5 μM dexamethasone to the cultured BMSCs and stimulates them for 96 hours, which can induce BMSCs to secrete inflammatory regulatory factors and immune regulatory factors. Adding 0.1 to 1 ng / mL of inonotus obliquus flavonoids to stimulate can increase the secretion of anti-inflammatory factors and immune regulatory factors and inhibit the secretion of pro-inflammatory factors.
[0027] 3. Mix aPL and induced BMSCs vesicle lysate to prepare multi-cytokine group sPL. The obtained factors are more diverse and more potent, which can better achieve the purpose of disease treatment.
[0028] 4. The present invention mainly prepares a sPL thermosensitive gel for the treatment of type 2 diabetes. The main components of the gel are poloxamer, chitosan and sPL. Poloxamer has good reversible gelation properties, biocompatibility, and low toxicity. It can flow freely at low temperatures, turn into gel at body temperature, and turn into liquid again when encountering low temperatures after gelation. This system can not only meet the needs of sPL low-temperature storage, but also be convenient for injection into the body, local administration according to the type of disease, increase local drug concentration, and avoid systemic effects. The combination of poloxamer and chitosan for gel preparation can better wrap sPL in the formed gel pore size, realize the sustained release effect of sPL factors, prolong the drug residence time, and improve bioavailability. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1is the SOD activity in aPL;
[0030] Figure 2 is the MDA content in aPL;
[0031] Figure 3 It is the sustained release of sPL thermosensitive gel factor;
[0032] Figure 4 This is the insulin resistance index of each group in the second week after injection;
[0033] Figure 5 This is the insulin resistance index of each group at 6 weeks after injection. DETAILED DESCRIPTION
[0034] The embodiments of the present invention are described in detail below. The following embodiments are implemented on the premise of the technical solution of the present invention, and detailed implementation schemes and specific operation processes are given, but the protection scope of the present invention is not limited to the following embodiments.
[0035] Example 1: Platelet enrichment and preparation of platelet lysate aPL
[0036] 1. Blood collection and processing
[0037] After the animals were anesthetized, whole blood was collected from the rats using a blood collection tube containing sodium citrate anticoagulant (V 血液 :V 抗凝剂 =9:1), the collected whole blood was transferred to a separation chamber at 4°C, and then the blood was equally divided into two portions, one of which was added with puerarin at a concentration of 0.15 μM and stored at 4°C for 24 h; the other portion was directly stored at 4°C for 24 h.
[0038] 2. Platelet enrichment:
[0039] The two portions of whole blood were centrifuged at 2000 rpm for 15 min to collect platelet-rich plasma (i.e., all the upper plasma after centrifugation); the platelet-rich plasma was centrifuged again at 4000 rpm for 20 min, and the enriched platelets in the lower layer were retained to ensure that the volume of the enriched platelets was 1 / 10 of the volume of the whole blood. The platelet precipitate attached to the bottom of the centrifuge tube was fully suspended by blowing the bottom with a pipette to obtain platelet-rich plasma (PRP).
[0040] 3. Preparation of platelet lysate aPL:
[0041] Add CaCl to the two portions of PRP prepared in step 2. 2and type III collagen, frozen at -80°C for 8 hours, thawed at 37°C for 5 minutes, and then repeated freezing and thawing 10 times. The process of repeated freezing and thawing once was freezing at -80°C for 1 hour and then thawing at 37°C for 5 minutes. The lysate after the last thawing was centrifuged at 6500rpm for 15 minutes, and the supernatant was taken to obtain fully activated platelet lysate aPL. Among them, CaCl 2 The concentration of puerarin was 25mmol / L, and the concentration of type III collagen in PRP was 20μg / mL. The aPL prepared from blood without puerarin treatment was numbered aPL-1, and the aPL prepared from blood treated with puerarin was numbered aPL-2.
[0042] Puerarin is a monomer component extracted from the traditional Chinese medicine Pueraria root. It is an isoflavone phytoestrogen with a chemical name of 8-β-D-glucose pyranose-4',7-dihydroxyisoflavone. Puerarin can effectively reverse chemically induced liver fibrosis, oxygen-containing groups can enhance liver protection activity, and also has a protective effect on acute liver damage induced by carbon tetrachloride. At the same time, it has many aspects of physiological activity. Puerarin has a protective effect on nephritis and renal failure models, and has a significant regulatory effect on nonspecific immunity, humoral immunity, and cellular immunity. It shows that puerarin has anti-inflammatory, anti-oxidative stress and immunomodulatory effects. Type 2 diabetes is a metabolic chronic disease characterized by insulin resistance and elevated blood sugar levels, which is mainly caused by systemic dysfunction of metabolic homeostasis. Puerarin is added in the process of preparing aPL of the present invention, and the prepared aPL has higher antioxidant and anti-inflammatory functions, which can provide an effective method for the treatment of diabetes.
[0043] 4. Detection of inflammatory regulatory factors and antioxidant substances in aPL
[0044] (1) The aPL-1 and aPL-2 obtained above were subjected to ELISA to evaluate the content of inflammatory regulatory factors such as IL-4, IL-10, TGF-β1 and IFN-γ. The IL-4, IL-10, TGF-β1 and IFN-γ in aPL-2 were significantly higher than those in aPL-1, with IL-4 and IL-10 reaching significant levels (P<0.05), and TGF-β1 and IFN-γ reaching extremely significant levels (P<0.01).
[0045] Table 1 Contents of inflammatory regulatory factors in aPL-1 and aPL-2
[0046]
[0047] (2) The aPL-1 and aPL-2 obtained above were subjected to SOD and MDA detection to evaluate the antioxidant effect of the prepared preparations. After the preparation of aPL-1 and aPL-2, the reaction system was prepared according to the instructions of the SOD detection kit (Solabo brand). After being incubated in a 37°C water bath for 30 minutes, the absorbance at 560 nm was measured using an enzyme reader. After the detection, the SOD activity was calculated according to the instructions. The reaction system was prepared according to the instructions of the MDA detection kit (Solabo brand). After being kept warm in a 100°C water bath for 60 minutes, it was cooled in an ice bath. After centrifugation at room temperature for 10 minutes at 10,000×g, the supernatant was aspirated and the absorbance at 532 nm and 600 nm was measured using an enzyme reader. After the detection, the MDA content was calculated according to the instructions. The SOD activity in aPL-1 and aPL-2 is as follows. Figure 1 As shown in Figure 2, the MDA content in aPL-1 and aPL-2 is as follows: Figure 2 The results showed that puerarin can effectively increase the SOD activity of aPL, reduce the MDA content, and thus improve the antioxidant capacity of aPL, that is, aPL-2 has a stronger antioxidant effect.
[0048] Example 2: Rat bone marrow mesenchymal stem cells (BMSCs) culture, induction and extracellular vesicle isolation
[0049] 1. BMSCs culture and induction
[0050] (1) Cell culture: BMSCs of passage P5 were cultured in DMEM / F12 medium containing 10% FBS at 37°C and 5% CO 2 nourish;
[0051] (2) Cell induction: BMSCs were divided into three groups: Group 1, Group 2, and Group 3. BMSCs in Group 1 were not induced. BMSCs in Group 2 were induced with induction fluid after they grew completely confluent (Day 0). The DMEM / F12 medium was replaced with induction fluid and stimulated for 96 hours. The induction method of Group 3 was the same as that of Group 2, except that 0.3 ng / mL of Inonotus obliquus flavonoids (IO) were added to the induction fluid for stimulation. Induction fluid composition: DMEM / F12 medium containing 10 μg / mL insulin and 1 μM dexamethasone.
[0052] Preparation method of inonotus obliquus flavonoids:
[0053] After grinding Inonotus obliquus (purchased from Special Medical Food Research and Development Center Co., Ltd.) into powder, 70% ethanol was used for heating reflux extraction at 75°C for 1 hour, and the supernatant was collected; after repeating the heating reflux extraction 3 times, the supernatants were combined and then heated and concentrated at 70°C to obtain Inonotus obliquus flavonoids.
[0054] 2. Extracellular vesicle isolation
[0055] (1) After induction, discard the induction solution and wash the cells twice with PBS. Replace the BMSCs in the three groups with DMEM / F12 basal medium and collect the supernatant after culturing for 12 hours. Centrifuge the supernatant at 300×g for 10 minutes at 4°C to remove the cells.
[0056] (2) Take the supernatant from the previous step and centrifuge it at 10,000 × g for 30 min at 4°C to remove cell debris;
[0057] (3) Transfer the supernatant after centrifugation to an ultracentrifuge tube and centrifuge at 100,000 × g for 75 min at 4°C. Retain the precipitate at the bottom of the tube. Resuspend the precipitate in pre-cooled PBS to obtain the extracellular vesicles. 2 The cell culture supernatant collected in the culture flask was 10 mL (the number of cells was about 4 × 10 6 100 mL of supernatant was collected and the cell vesicles were resuspended in 4 mL of PBS to obtain a vesicle suspension. The vesicles stimulated with IO were recorded as IO vesicles, and the vesicles without IO stimulation were recorded as non-IO vesicles.
[0058] 3. Vesicle lysis, including detection of anti-inflammatory factors, pro-inflammatory factors and immunomodulatory factors
[0059] The vesicles were ultrasonically lysed for 20 min at 4 °C using an ultrasonic disruptor and filtered with a 0.22 μm filter membrane to obtain vesicle lysate. 1 mL of lysate sample was taken for ELISA to detect the concentrations of adiponectin (ADPN), omentin, resistin, interleukin 6 (IL-6), and transforming growth factor β1 (TGF-β1). The results are shown in Table 2. The results showed that after vesicle lysis, the expression levels of anti-inflammatory factors (ADPN, Omentin) and immunomodulatory factors (TGF-β1) in group 3 were significantly higher than those in groups 1 and 2, and the expression levels of pro-inflammatory factors (Resistin, IL-6) were significantly lower than those in groups 1 and 2. This indicates that IO can effectively regulate the expression of inflammatory factors and immunomodulatory factors during the induction of BMSCs, making it more suitable for the treatment of type 2 diabetes.
[0060] Table 2 Contents of anti-inflammatory factors, pro-inflammatory factors and immunomodulatory factors in each vesicle lysate
[0061]
[0062] Note: Group 1 is uninduced BMSC vesicle lysate, Group 2 is non-IO induced BMSC vesicle lysate, and Group 3 is IO induced BMSC vesicle lysate. * indicates significant difference compared with Group 1, ** indicates extremely significant difference compared with Group 1; # indicates significant difference compared with Group 2, ## indicates extremely significant difference compared with Group 2.
[0063] Example 3: Preparation of sPL thermosensitive gel
[0064] 1. The aPL-2 prepared in Example 1 and the IO vesicle suspension prepared in Example 2 were mixed in a volume ratio of 1:1 to obtain an sPL mixed solution, which was stored at -80°C.
[0065] Preparation of sPL thermosensitive gel:
[0066] The thermosensitive gel was prepared according to the method in the literature "Preparation and sustained release study of aFGF sulfonated chitosan oligosaccharide thermosensitive gel".
[0067] (1) Preparation of poloxamer gel: Weigh 30 g of BASF poloxamer 407 and 5 g of poloxamer 188, stir them evenly in 100 mL of ultrapure water, swell them at 4°C overnight, sterilize them by high pressure, and store them at 4°C for later use.
[0068] (2) Preparation of sulfonated chitosan oligosaccharide solution: Weigh 250 mg of sulfonated chitosan oligosaccharide, dissolve in 10 mL of ultrapure water, filter through 0.22 μm for sterilization, and store at 4°C for later use.
[0069] (3) Preparation of chitosan solution: Sterile chitosan powder was weighed, swollen with 1% glacial acetic acid solution, and then adjusted to pH = 6 with NaOH to prepare a 0.5% chitosan solution.
[0070] (4) Preparation of chitosan-poloxamer gel: chitosan solution and poloxamer gel were fully mixed at a volume ratio of 3:2 at 2-8°C to obtain chitosan-poloxamer gel.
[0071] (5) Preparation of thermosensitive gel containing sPL: chitosan-poloxamer gel and sPL mixed solution were mixed in a volume ratio of 1:6 to prepare sPL thermosensitive gel.
[0072] 2. Detection of sustained release of sPL thermosensitive gel: 5 mL of sPL thermosensitive gel was added to a centrifuge tube, solidified at 37°C, and 1 mL of PBS buffer was slowly added along the tube wall. The whole system was centrifuged at 12000g for 10 min at 0.5d, 1d, 3d, 5d, 7d, 10d, and 14d, and the supernatant was collected and 1 mL of PBS buffer was added. The IL-10 content in the supernatant taken out each time was determined by ELISA kit, and the cumulative release of IL-10 was calculated.
[0073] The sustained release of factors in sPL thermosensitive gel is as follows Figure 3 As shown in the figure, it can be seen that the release of IL-10 is basically in an increasing state, and the cumulative release rate reaches 70%, indicating that the sPL thermosensitive gel has a certain slow-controlled release effect.
[0074] Example 4: Study on the therapeutic effect of sPL thermosensitive gel on type 2 diabetes
[0075] 1. Establishing the model using the streptozotocin (STZ) method
[0076] 100 male Wister rats, 10 rats were fed with maintenance feed (blank control group), 90 rats were fed with high-fat and high-sugar feed for 6 weeks (model group), free food and water, 6 weeks later, rats fasted for more than 12 hours, fasting intraperitoneal injection of 35mg / kg STZ. After the injection, high-fat and high-sugar feeding continued for 1 week, 12h fasting blood sugar or random blood sugar was tested, fasting blood sugar ≥ 7.0mmoL / L or random blood sugar > 11.1mmoL / L was considered successful modeling.
[0077] 2. Animal grouping, treatment and effect testing
[0078] (1) Grouping and treatment: Among the 90 modeling animals, 60 successfully modeled animals were selected and randomly divided into 6 groups, with 10 animals in each group, namely the model control group (M group), aPL treatment group (aPL group), IO vesicle lysate treatment group (IO group), sPL treatment group (sPL group), sPL thermosensitive gel treatment group (sPL-Gel group), and factor-free gel treatment control group (Gel group). Ten healthy animals were used as the healthy control group (C group). When treating each group of animals, the corresponding product was injected into the periphery of the dorsal pancreatic artery, and the injection volume was 0.2 mL / animal. The healthy control group and the model control group were injected with the same volume of normal saline, and the treatment was 1 time in total. Various indicators were tested starting from the second week after treatment. Among them, the sPL group was injected with a sPL mixed solution obtained by mixing aPL-2 and IO vesicle suspension in a volume ratio of 1:1.
[0079] (2) Blood glucose testing: Fasting blood glucose testing was performed in each group at 2 weeks and 6 weeks after injection. Rats were fasted overnight before testing, and blood was collected from the tail vein. Fasting blood glucose levels were tested using blood glucose test strips.
[0080] The changes in blood glucose of diabetic mice after treatment are shown in Table 3. The results show that the blood glucose index of the treatment group was significantly better than that of the model group. At the 6th week, it was still maintained at a low level, indicating that aPL, IO vesicle lysate, sPL and sPL thermosensitive gel can effectively relieve the symptoms of hyperglycemia. The effect of sPL thermosensitive gel is significantly better than that of aPL and IO vesicle lysate. At the same time, the effect of sPL thermosensitive gel is significantly better than that of liquid sPL.
[0081] Table 3 Changes of blood sugar in diabetic mice after treatment ( mmoL / L)
[0082]
[0083]
[0084] Note: Compared with group C, * P<0.05, ** P<0.01; compared with group M, # P<0.05, ## P<0.01; compared with the sPL group, & P<0.05, && P<0.01; compared with the sPL-Gel group, ^P<0.05, ^^P<0.01.
[0085] (3) Insulin resistance index detection: At 2 weeks and 6 weeks after injection, rats in each group were fasted overnight, blood was collected from the tail vein, and fasting blood glucose values were measured using blood glucose test strips, and insulin levels were measured using ELISA kits. Insulin resistance index = fasting insulin value × fasting blood glucose value / 22.5.
[0086] The insulin resistance index of each group in the second week after injection is as follows Figure 4 As shown in Figure 2, the insulin resistance index of each group at week 6 after injection was as follows: Figure 5 The results showed that the insulin resistance index (HOME-IR) in the treatment group was significantly lower than that in the model group. At the 6th week, the same trend was maintained, indicating that aPL, IO vesicle lysate, sPL and sPL thermosensitive gel can effectively alleviate the insulin resistance state. The effect of sPL is significantly better than that of aPL and IO vesicle lysate. At the same time, the effect of sPL gel is significantly better than that of liquid sPL, and the value is close to that of the healthy control group.
Claims
1. A method for preparing a sPL thermosensitive gel for treating type 2 diabetes, characterized in that: The method comprises the following steps:
1. Add puerarin to the blood and store it at 4°C for 24 to 36 hours; then centrifuge the blood to collect platelet-rich plasma; lyse the platelet-rich plasma to prepare platelet lysate aPL; 2. After the bone marrow mesenchymal stem cells are cultured to complete fusion, the culture medium is replaced with induction solution and the induction culture is continued for 96 to 98 hours; The induction solution is a DMEM / F12 basal culture medium containing 5 μg / mL to 5 mg / mL insulin, 0.5 to 5 μM dexamethasone and 0.1 to 1 ng / mL Inonotus obliquus flavonoids; 3. Extracting extracellular vesicles from the induced bone marrow mesenchymal stem cells and resuspending them in PBS to obtain a vesicle suspension; 4. ultrasonically lyse the vesicle suspension obtained in step 3 to obtain a vesicle lysate, and then mix the platelet lysate obtained in step 1 with the vesicle lysate to obtain an sPL mixed solution; 5. Prepare chitosan-poloxamer gel. Mix the sPL mixed solution with the chitosan-poloxamer gel to prepare the sPL thermosensitive gel.
2. The method for preparing a sPL thermosensitive gel for treating type 2 diabetes according to claim 1, characterized in that: Step 1: The concentration of puerarin in the blood is 0.05-0.2 μM.
3. A method for preparing a sPL thermosensitive gel for treating type 2 diabetes according to claim 1 or 2, characterized in that: The preparation method of platelet lysate aPL in step 1 is: CaCl2 and type III collagen were added to platelet-rich plasma, respectively, and frozen at -80℃ for 8-9 hours, thawed at 37℃ for 5-10 minutes, and then frozen and thawed 10 times. The process of repeated freezing and thawing once was: freezing at -80℃ for 1 hour and then thawing at 37℃ for 5-10 minutes; the lysate after the last thawing was centrifuged, and the supernatant was taken to obtain fully activated platelet lysate aPL. The concentration of CaCl2 in PRP was 25mmol / L, and the concentration of type III collagen in PRP was 20μg / mL.
4. The method for preparing the SPL thermosensitive gel for treating type 2 diabetes according to claim 3, characterized in that: The method for extracting extracellular vesicles in step 3 is: The induced bone marrow mesenchymal stem cells were washed, cultured with DMEM / F12 basal medium for 12 to 14 hours, and the culture medium was collected and centrifuged. The supernatant was taken and centrifuged at 10,000 × g at 4°C to remove cell debris; The supernatant was then transferred to an ultracentrifuge tube and ultracentrifuged at 100,000×g at 4°C for 75 to 80 min. The precipitate at the bottom of the tube was retained, which was the extracellular vesicles.
5. The method for preparing the SPL thermosensitive gel for treating type 2 diabetes according to claim 1, characterized in that: In step 4, the platelet lysate and the vesicle suspension are mixed in a volume ratio of 1:(1-2).
6. The method for preparing the SPL thermosensitive gel for treating type 2 diabetes according to claim 5, characterized in that: In step 5, the volume ratio of the sPL mixed solution to the chitosan-poloxamer gel is 1:(5-9).
7. A method for using the sPL thermosensitive gel prepared by the method of claim 1, characterized in that: The method is: injecting sPL thermosensitive gel into the periphery of the dorsal pancreatic artery of mice.
8. The method for using the sPL thermosensitive gel according to claim 7, characterized in that: The injection dosage is 0.2 mL / mouse.
Citation Information
Cited By
Sponge patch as well as preparation method and application thereof
CN119139532A
